Research
Energy balance
Tirzepatide showed a favourable safety profile, without increasing the risk of serious adverse events or impacting mortality rates.
Tirzepatide can be used safely in obesity management without significant risk of serious side effects.
StrongSupportsmedium confidence
Tirzepatide showed a favourable safety profile, without increasing the risk of serious adverse events or impacting mortality rates.
Why this rating
Based on a systematic review and meta-analysis of randomized controlled trials.
Source
Exploring the Efficacy and Safety of Tirzepatide in Obesity Management and Cardiometabolic Risk Factors: A Comprehensive Systematic Review and Meta‐Analysis
Jian‐Ying Wang et al. · Clinical Obesity · 2025
DOI 10.1111/cob.70036
Meta-analysisCited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Tirzepatide significantly reduced body weight compared to placebo, with a total pooled mean difference of -11.62 kg (95% confidence interval: -14.24 to -9.01, p < 0.001).Strong
- In the highest dosage group of 15 mg, 88.1%, 63.3%, and 51.8% of participants achieved weight reductions exceeding 5%, 10%, and 15% respectively.Strong
Related findings · Energy balance
- Achieving a total body weight loss of 10-15% (or >10-15 kg) through Total Diet Replacement (TDR) induces remission of Type 2 Diabetes in individuals with short-duration disease.Strong
- Bariatric surgery is superior to medical management alone for inducing significant long-term weight loss, remission of type 2 diabetes, and reduction in mortality for patients with BMI ≥ 40 or ≥ 35 with comorbidities.Strong
- Achieving type 2 diabetes remission requires significant weight loss (≥15 kg) via major caloric restriction, independent of macronutrient composition.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →